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ABSTRACT
Objectives: Pulmonary carcinoid (PC) is a rare
tumour with good prognosis following surgical
resection. However, little is known regarding patient
characteristics and use of other treatments modalities.
Our objective was to review patient characteristics,
treatment and survival for patients with PC and
contrast these results with other forms of non-small
cell lung cancer (NSCLC).
Setting: Audit data from UK National Lung Cancer
Audit (NLCA) 2008–2013.
Participants: 184 906 lung cancer cases were
submitted to the NLCA.
Outcome measures: Primary outcome—survival
rates between PC and NSCLC. Secondary outcome—
differences in performance status, lung function and
treatment modality between PC and NSCLC.
Results: PC histology was recorded in 1341 (0.73%)
patients and non-carcinoid NSCLC histology in 162 959
(87.4%) cases. 91% of patients with PC had good
performance status (Eastern Cooperative Oncology Group
(ECOG) 0–1), compared with only 53% of NSCLC. 66%
of PC had localised disease. Of all PC cases, 77% were
treated with surgery, 6.2% received chemotherapy and
3.6% received radiotherapy, with the remainder treated
with best supportive care. Overall 1-year and 3-year
survival rates for PC were 92% and 84.7%, respectively.
In contrast, 1-year and 3-year survival rates for NSCLC
were 36.2% and 15.6%, However, 3-year survival for PC
markedly decreased with worsening performance status
and advanced disease to 23.8% for performance status
ECOG 3–4 and 33.6% for stage IV disease.
Conclusions: In contrast to other forms of NSCLC, the
majority of patients with PC present with good
performance status, preserved lung function and early
stage disease amenable to surgical resection. However,
1 in 5 patients with PC has metastatic disease which is
associated with poor prognosis, as is poor performance
status at presentation. We believe these data will help
clinicians provide accurate prognostic predictions
stratified according to patient characteristics at
presentation, as well as guide future clinical trials.
INTRODUCTION
Pulmonary carcinoid (PC) is a rare tumour
which is estimated to account for only
around 1–2% of all lung cancers1 with an
incidence in Europe of 0.2 per 100 000 per
year.2 The pathological deﬁnition is usually
based on the WHO classiﬁcation ﬁrst pub-
lished in 1967 and most recently updated in
the fourth edition. An absence of extensive
necrosis and a mitotic count of <10 per high
power ﬁeld is used to differentiate PC from
high-grade large cell and small cell neuroen-
docrine tumours. PC can be further subdi-
vided into typical and atypical on the basis of
mitotic count and the presence/absence of
focal necrosis, although this can only be reli-
ably assessed on a surgical specimen, and
there remains interobserver variability in this
pathological interpretation.3
Overall 5-year survival for lung cancer is
poor at 9.5%,4 but PC is a distinct subgroup
of tumours which appear to have a more
favourable outcome, especially after surgery
with a view to a complete R0 resection.2 In
2003, a Surveillance, Epidemiology, and End
Results (SEER) analysis from the USA
reported a 5-year survival of 74% for patients
diagnosed with tracheal and bronchial car-
cinoid from 1973 to 1999.5 A recent SEER
analysis of 441 patients with atypical carcin-
oid reported a surgical resection rate of 78%
with 3-year survival of 67%.6 A smaller case
series which included 142 patients with
typical and atypical PC reported a surgical
resection rate of 72% with a 5-year survival
rate of 89% for typical carcinoid and 75%
for atypical carcinoid.7 Surgical case series
tend to report even higher survival rates; a
Japanese registry report of tracheal and
Strengths and limitations of this study
▪ Very large data set reviewed.
▪ Highly representative and detailed analysis of
pulmonary carcinoid tumours.
▪ Unable to differentiate between typical and atyp-
ical carcinoid tumours.
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bronchial carcinoid tumours reported a postoperative
10-year survival of 82% for typical carcinoid and 59% for
atypical carcinoid.8
While these case series provide an interesting insight
into the management of carcinoid tumours, the rela-
tively small number of patients and retrospective nature
of data collection limit general applicability. In addition,
relatively little is known regarding patient characteristics
in PC and other treatment modalities such as chemo-
therapy or radiotherapy. To address this, we performed
an analysis of patients with PC submitted to the UK
National Lung Cancer Audit (NLCA). We report on
patient characteristics, treatments and contrast the
results with other forms of non-small cell lung cancer
(NSCLC).
METHODS
Data source
The NLCA is commissioned by the Healthcare Quality
Improvement Partnership (HQIP) and collects data on
all patients with lung cancer in England and Wales. It
was set up to record information about activity, process
and outcomes in lung cancer and explain the wide varia-
tions in outcome across the UK.9 The database includes
112 ﬁelds covering patient demographics, referral pat-
terns, investigations, performance status (PS) using the
Eastern Cooperative Oncology Group (ECOG) scale,
lung function, stage of disease, treatment modalities of
surgery (not including endobronchial interventions),
chemotherapy and radiotherapy, and survival. Data are
collected by an online tool (LUCADA database) from all
hospital managing lung cancer in the UK. Annual
reports are then sent to all hospital chief executives and
medical directors, primary care trusts, cancer commis-
sioners, MDT and network leads.9
As this is a review of data from a national audit, no
ethical approval is required.
Patient population
All patients from England and Wales submitted to the
NLCA between 2008 and 2013 with recorded histology
of PC were included in the analysis. The NLCA database
only allows the selection of one Systematized
Nomenclature of Human Medicine (SNOMed) III code
(M8240/3) for PC which equates to carcinoid ‘not
otherwise speciﬁed’. The data set did not differentiate
between typical and atypical carcinoid tumours. All cases
were primary pulmonary tumours. No extra-PC tumours
or pulmonary metastases from other sites were included.
A comparative analysis was performed using patients
diagnosed with non-carcinoid NSCLC (all other cell
types excluding small cell cancer).
All staging referred to in this paper is preintervention
staging.
Statistical analysis
Statistical analysis was performed using SPSS V.19.
Continuous variables are presented as mean (SD).
Survival was calculated using linked ofﬁce of national
statistics data and is presented as proportions at speci-
ﬁed time intervals from diagnosis using Kaplan-Meier
methods.
RESULTS
Every hospital in England and Wales participated in the
NLCA during the study period and a total of 184 906
lung cancer cases were submitted. PC histology was
recorded in 1341 (0.73%) patients and NSCLC (as
deﬁned in the methods) in 162 959 (87.4%) cases.
Patient characteristics
The patient characteristics for the two groups are shown
in table 1.
Age and gender were recorded in all cases. Mean
(SD) age at the time of diagnosis for patients with PC
was 62 (15) years with 62% female, whereas mean (SD)
age for NSCLC was 72 (11) years, with 44% female. PS
was recorded in 88% cases and stage in 81% cases.
Ninety-one per cent of patients with PC had good PS
(ECOG 0–1) and 66% had localised disease (stage I–II).
In contrast, only 53% of patients with NSCLC had good
PS and 24% had localised disease. Mean (SD) lung func-
tion as measured by the forced expiratory volume in 1 s
(FEV1) was 2.27 L (0.83) in the PC group and 1.71 L
(0.72) in the NSCLC group.
Treatment
Treatment data are summarised in table 1. Staging is
classiﬁed as localised (stage I–II), regional (stage III)
Table 1 Patient characteristics, tumour stage and
treatment
Carcinoid NSCLC
N 1341 161 618
Patient characteristics
Age—mean (SD) 62 (15) 72 (11)
Female 62% 44%
Performance status 0–1 91.4% 52.6%
FEV1—mean (SD) 2.27 (0.83) 1.71 (0.72)
Stage
Localised 65.7% 20.4%
Regional 6.3% 22.3%
Metastatic 8.7% 43.1%
Unknown 19.2% 14.2%
Treatment
Surgery 76.9% 14.2%
Chemotherapy 6.2% 25.7%
Radiotherapy 3.6% 28.4%
No treatment recorded 13.3% 31.7%
FEV1, forced expiratory volume in 1 s; NSCLC, non-small cell lung
cancer.
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and distant (stage IV). Overall, 87% of the patients with
PC received anticancer treatment (surgery, radiotherapy
or chemotherapy). In contrast, 68.3% of patients with
NSCLC received active treatment. The majority of
patients with PC (77%) were treated with surgery, 6.2%
received chemotherapy and 3.6% received radiotherapy.
This is in contrast to NSCLC, where only 14% of patients
had surgery, 26% received chemotherapy and a further
28% received radiotherapy.
Survival
Overall 1-year and 3-year survival rates for PC were 92%
and 84.7%, respectively. In contrast, 1-year and 3-year
survival rates for NSCLC were 36.2% and 15.6%, respect-
ively. Survival rates by PS are shown in table 2. There was
a stepwise decrease in survival for PC from 1-year and
3-year survival rates of 93.5% and 85.2%, respectively, for
PS 0–1 patients down to 41.7% and 2.4%, respectively,
for poor PS (ECOG 3–4) patients. A very similar pattern
of survival rates was seen for localised (stage I–II),
regional (stage III) and distant (stage IV) PC disease
(table 3). Survival in patients with NSCLC also
decreased with worsening PS and more advanced stage,
but in contrast to carcinoid, survival rates were much
lower (tables 2 and 3).
DISCUSSION
We analysed data submitted to the NLCA to more
clearly deﬁne patient characteristics, treatment modal-
ities and survival of this subgroup of lung cancers, which
we contrasted to patients with non-carcinoid NSCLC. We
conﬁrmed that PC is a rare tumour and constituted <1%
of all lung cancers in our data set. We demonstrated that
the majority (68%) of patients with PC are female,
which is in keeping with the previous SEER database
reports,5 6 but higher than smaller case series10 11 which
likely reﬂects the more representative nature of the
NLCA and SEER databases. We report, for the ﬁrst time,
that patients with PC have excellent PS at presentation
and well-preserved lung function. In addition, the majo-
rity (66%) of patients with PC in this study presented
with early stage (localised) resectable disease, although
10% had metastatic disease at presentation. These ﬁnd-
ings are largely consistent with the stage distribution
reported in the SEER analysis of tracheal and bronchial
PC5 where two-thirds of patients had localised disease at
presentation; however, the proportion of patients with
metastatic disease in this study was only 0.5% for the
period 1992–1999. This could be explained by selective
submission of surgical cases, whereas data submitted to
the NLCA are for all patients with lung cancer, irrespect-
ive of treatment modality. The patient characteristics for
the PC group were in stark contrast to the NSCLC
group. The mean age for the patients with NSCLC was
10 years older than the PC group and only half of
patients had good PS. The lung function, as measured
by FEV1, was 25% lower than the PC group. Similarly,
only one in four patients in the NSCLC group presented
with localised disease and over 40% had metastatic
disease at presentation.
Surgery is recommended as ﬁrst-line treatment in
locoregional PC.3 12 In our study, three-quarters of
patients with PC underwent surgery, reﬂecting the stage
distribution and ﬁtness of this group of patients. The
treatment of metastatic PC is less clearly deﬁned.
Systemic therapy is generally recommended for meta-
static disease; however, the results with chemotherapy
have been largely disappointing.3 Given that chemother-
apy is not routinely used or recommended in the adju-
vant setting as it does not improve survival,13 we can
infer from our results that most patients with metastatic
disease are treated with chemotherapy, despite the poor
reported response rates with this treatment. To the best
of our knowledge, this is the ﬁrst time that the use of
chemotherapy has been reported on a large scale for
Table 2 One-year and 3-year survival rates (%) stratified according to performance status
Carcinoid NSCLC
ECOG 1-year 3-year ECOG 1-year 3-year
0–1 (n=1003) 93.5 85.2 0–1 (n=72 065) 55.3 26.7
2 (n=70) 75.2 57.4 2 (n=28 499) 26.9 8.3
3–4 (n=24) 41.7 23.8 3–4 (n=36 528) 11.1 2.4
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer.
Table 3 One-year and 3-year survival rates (%) stratified according to stage
Carcinoid NSCLC
STAGE 1-year 3-year STAGE 1-year 3-year
Localised (n=429) 96.4 87.7 Localised (n=33 040) 73.0 44.4
Regional (n=85) 75.8 63.1 Regional (n=26 070) 40.9 12.5
Metastatic (n=117) 54.9 33.6 Metastatic (n=69 598) 16.7 3.5
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer.
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patient with PC tumours. Similarly, there is very little in
the literature relating to radiotherapy treatment in PC
and recent guidelines do not refer to this treatment
modality.3 The recent report by Steuer and colleagues
found that 12.5% of patients with atypical PC received
radiotherapy which is higher than the 3.6% radiotherapy
treatment rate found in our study and is likely due to
the more aggressive nature of atypical PC tumours.
Our data conﬁrm that the prognosis for PC is gener-
ally excellent, with overall 1-year and 3-year survival rates
of 92% and 84.7%, respectively. Once again, this is in
stark contrast to other forms of NSCLC where the 1-year
survival rate was only 36.2%. We found that stage at pres-
entation in PC is an important determinant of survival
which is in keeping with the ﬁndings of previous
studies,5 6 but we also report that PS is an equally
important predictor of survival for patients with PC. This
complements recent work from the European
Association of Thoracic Surgeons (ESTS) who found PS
was a predictor for mortality in this group.14 Although
the majority of our patients with PC have good PS at
presentation, the small proportion with poor PS in our
study had a 1-year survival of only 42%. This group of
patients may have had other comorbidities rendering
them unﬁt for any form of active anticancer treatment
which could explain the poor survival.
The current study has a number of strengths but also
potential limitations. The data set provided by the NLCA is
large, with mostly excellent levels of data completeness,
but there are some missing data; and also no data were
available on patients presenting with carcinoid syndrome.
Additionally no information was available on regional
control rates or treatment failure. Although the missing
data could impact on results, we feel this is likely offset by
the size of the data pool. A further limitation is the inabil-
ity to discriminate between typical and atypical carcinoid
tumours in this data set.
However, it is felt that overall it provides a highly rep-
resentative and detailed analysis of all forms of PC
tumours, irrespective of treatment given. However, the
inability to record typical versus atypical carcinoid hist-
ology limits the study’s ability to differentiate treatment
and outcomes by these two cell types. Also, the data
available categorise cancer by stage rather than T, N, M
status. In addition, the details of chemotherapeutic regi-
mens and radiotherapy dosing schedules were not
recorded in the NLCA during the time of this analysis.
In conclusion, our large and detailed data set demon-
strate that, in contrast to other forms of NSCLC, the major-
ity of patients with PC present with good PS,
well-preserved lung function and early stage disease
leading to high rates of surgical resection. However, one in
ﬁve patients have local or regional metastatic disease
which is associated with a poor prognosis, as is poor PS at
presentation. We believe that these data will help clinicians
provide more accurate prognostic predictions stratiﬁed
according to patient characteristics at presentation. The
data shown here provide reassurance to patients and
clinicians that patients with carcinoid with early disease
who have surgery enjoy high levels of survival; however,
clinical trials are needed of newer treatment in metastatic
disease.
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